Recce Pharmaceuticals (FRA:R9Q) Short Interest


FRA:R9Q Recce Pharmaceuticals Ltd FRA:R9Q
30 GF Score
Price €0.20
! 4 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:R9Q vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Recce Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recce Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's Short Interest falls into.


FRA:R9Q
30GF Score
Recce Pharmaceuticals Ltd FRA:R9Q
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals Business Description

Other Exchanges RCE:Australia
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
30GF Score

Get the complete analysis for FRA:R9Q

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price